"versionIdentifier","instanceType","uuid:ID","rationale","id"
"2","StudyVersion","d74c6b00-7770-4b5f-8e81-b06b4a3f30c3","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1"
